The original statement was published in the ACMG newsletter in 1996.
This document was retired by the ACMG Board of Directors as of 27 April 2020 with the following addendum:
References
Lobaugh NJ, Karaskov V, Rombaugh V, et al. Piracetam therapy does not enhance cognitive functioning in children with Down syndrome. Arch Pediatr Adolesc Med. 2001;155:442–448.
Bull MJ, Committee on Genetics. Health supervision for children with Down syndrome. Pediatrics. 2011;128:393–406. Reaffirmed in Pediatrics. 2018;141:e20180518.
Author information
Authors and Affiliations
Consortia
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Correspondence: ACMG (documents@acmg.net)
Rights and permissions
About this article
Cite this article
Balwani, M., the American College of Medical Genetics and Genomics (ACMG) Professional Practice and Guidelines Committee. Addendum: Statement on nutritional supplements and piracetam for children with Down syndrome. Genet Med 22, 2127 (2020). https://doi.org/10.1038/s41436-020-0847-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41436-020-0847-9
